Please ensure Javascript is enabled for purposes of website accessibility

Why Horizon Pharma plc Shares Jumped 68% in 2015

By Todd Campbell - Jan 6, 2016 at 8:02AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A spate of acquisitions is driving sales and profit higher for this mid-cap pharmaceutical company.

Image source: Horizon Pharma plc.

What: Revenue- and profit-boosting acquisitions drove record sales and profit last year, leading to shares in Horizon Pharma plc (HZNP 0.55%) soaring 68.1% in 2015, according to Capital IQ.

So what: Thanks to a M&A-hungry approach to growth, revenue at Horizon Pharma plc surged 202% year over year to $226.5 million in the third quarter.

The biggest reason behind the increase is Duexis, a combination of ibuprofen and famotidine that racked up sales of $56.9 million, up 150% from last year.

Revenue also remained strong for Vimovo, a combination drug consisting of the NSAID Motrin and the antacid Pepcid that is used to fight ulcers in arthritis patients at risk of developing NSAID-related ulcers. Sales of Vimovo totaled $46.8 million in the quarter.

Additionally, sales of Pennsaid 2% reached $43.9 million, up 49% from the second quarter, and sales of Rayos grew 106% quarter over quarter to $11.7 million.

Image source: Horizon Pharma plc.

Leveraging the spike in sales against fixed costs resulted in Horizon Pharma delivering non-GAAP EPS of $0.70 in Q3, a whopping 268% improvement from last year.

Now what: A big part of Horizon Pharma's strategy has been the acquisition of existing medications in order to rebrand them with higher price tags. That business model has come under fire following the high-profile exploits of Martin Shkreli, who was made infamous this fall for buying a decades-old drug used to fight parasitic infection only to increase its price by more than 5,000%.

Because this rebranding strategy is increasingly drawing the ire of insurers and politicians, it's uncertain whether any blowback could damage Horizon Pharma's cash cows.

Although that risk shouldn't be ignored, investors should know that the company isn't resting on its laurels. This summer, the company launched a now-failed bid to acquire rival Depomed Inc(ASRT 0.00%) and its platform of pain drugs, and in December, Horizon Pharma inked a $510 million deal to buy privately held Crealta Holdings to get its hands on Krystexxa, a therapy for gout.

Given the company has over $680 million in cash and management is predicting that its sales will hit $2 billion in 2020, it would appear there's still a lot of potential growth ahead for this company, assuming, of course, that drug prices don't end up falling significantly lower. 

Todd Campbell owns shares of DepoMed,. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Horizon Therapeutics Public Limited Company Stock Quote
Horizon Therapeutics Public Limited Company
HZNP
$67.47 (0.55%) $0.37
Depomed, Inc. Stock Quote
Depomed, Inc.
ASRT
$3.80 (0.00%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.